November 20th, 2009 by Kevin A. Barnes
As part of $3K in 3 Weeks, here is another in a series of articles on current issues and topics related to Crohn’s disease and ulcerative colitis.
Did you know that biologics such as Remicade, Humira, and Cimzia – used in the treatment of Crohn’s disease and ulcerative colitis – are governed by different rules and laws than other traditional medications? As a result, there currently are no approved generic biologics in the U.S. So while you might be able to buy a generic version of a brand name pain killer or blood pressure medication, you can’t buy generic Remicade (at least not legally).
Why are generic biologics not available, and is that likely to change?
To answer those questions, we need to start with a quick history lesson: The generic drug industry arose in 1984 when the Hatch-Waxman Act made it much easier (and much less expensive) for qualified companies to produce a molecularly identical version of a drug after its patent had expired. (Prior to Hatch-Waxman, a company wishing to manufacture a generic drug would have had to repeat the full – and costly – clinical studies and the same FDA approval process that the original manufacturer went through.) Read the rest of this entry »
Categories: $3K in 3 Weeks, Crohn's Disease, Science | Tags: biologics, Cimzia, Crohn's Disease, generic drugs, H.R. 3962, Hatch-Waxman Act, health care reform, Humira, ibd, Remicade, ulcerative colitis
Comments: No Comments »
November 18th, 2009 by Kevin A. Barnes
As part of $3K in 3 Weeks, here is the first in a series of articles on current research initiatives related to Crohn’s disease and ulcerative colitis.
The Human Gut Microbiome Initiative, based at the Genome Center of Washington University in St. Louis, is the first major investigation into the thousands of species of bacteria that live in the human digestive system.
What’s a microbiome? The “microbiome” is defined as all bacteria in the human body, as well as all the products they make. To put this in perspective, scientists estimate that as much as 90% of the cells in the human body are actually bacteria. In the past, since most of the species of bacteria found in the human body could not be cultured (grown outside the body for study), we’ve been essentially clueless about how those bacteria functioned and their potential role in the human body. Read the rest of this entry »
Categories: $3K in 3 Weeks, Crohn's Disease | Tags: $3K in 3 Weeks, CCFA, Crohn's Disease, cure, Human Gut Microbiome Initiative, ibd, Las Vegas half marathon, Team Challenge, ulcerative colitis
Comments: No Comments »
November 15th, 2009 by Kevin A. Barnes
$3K in 3 Weeks is a special effort I’ve established to raise both awareness and at least $3,000 to help defeat Crohn’s disease and ulcerative colitis — hence $3K in 3 Weeks.
The effort runs from today (Sunday, November 15) through Sunday, December 6 when I will run the 13.1-mile Las Vegas Rock ‘n’ Roll Half Marathon to demonstrate my commitment to defeating Crohn’s and colitis. (What are Crohn’s disease and ulcerative colitis? Read an overview of these diseases and their impact at the end of this article. )
In recent years, we’ve seen dramatic advances in the understanding of these devastating diseases, to the point where our knowledge has already begun to improve the lives of those with Crohn’s and colitis (an estimated 1.4 million people in the U.S. alone). And recently one researcher after another has begun telling us the same thing:
“We know what remains to be done — the only thing standing between us and a cure is money.”
That’s right — money has become the critical factor in helping find a cure. Here’s how you can help: Read the rest of this entry »
Categories: $3K in 3 Weeks, Crohn's Disease | Tags: $3K in 3 Weeks, CCFA, Crohn's Disease, cure, ibd, Las Vegas half marathon, Team Challenge, ulcerative colitis
Comments: No Comments »
November 5th, 2009 by Kevin A. Barnes
A new study published in the New England Journal of Medicine yesterday identifies three different genetic mutations that appear to be associated with early-onset inflammatory bowel disease (IBD).
Researchers examined two families which had a total of nine cases of early-onset IBD and identified “three distinct homozygous mutations in genes IL10RA and IL10RB, encoding the IL10R1 and IL10R2 proteins, respectively, which form a heterotetramer to make up the interleukin-10 receptor.” They also tested a small sample of IBD patients from outside those two families to determine if similar genetic mutations could be involved in other cases of IBD. The researchers go on to theorize that in these particular patients a lack of interleukin-10 signaling is “the principal malfunction and is a likely cause of inflammatory bowel disease in patients with IL10R2 deficiency.” Read the rest of this entry »
Categories: Crohn's Disease | Tags: Crohn's Disease, genetics, ibd, interleukin-10, NEJM, ulcerative colitis
Comments: 1 Comment »
September 9th, 2009 by Kevin A. Barnes
As happens way too frequently with Crohn’s disease, this afternoon I found myself being admitted to the hospital. The health of a Crohn’s patient can seem to be going well for months (or even years) and then without warning everything goes downhill in a matters of days (or even hours).
Ever since I started running half marathons with Team Challenge in 2008, I’ve been preaching about the many and varied horrors that can accompany living with Crohn’s disease. And now – once again – I find myself experiencing that crap firsthand. Read the rest of this entry »
Categories: Crohn's Disease | Tags: CCFA, Crohn's Disease, Froedtert Hospital, ibd, patient, Team Challenge
Comments: 11 Comments »
